28-Oct-2026 17:32:45
CONCORD BIOTECH Q2 CONCALL: MANAGEMENT EXPECTS FY27 REVENUE GROWTH ABOVE 18–19%, TARGETS 38–40% MEDIUM-TERM EBITDA MARGIN, ₹300 CR INJECTABLE REVENUE & ₹400–500 CR DERMATOLOGY BUSINESS
• MANAGEMENT EXPECTS FY27 REVENUE GROWTH SLIGHTLY ABOVE ITS HISTORICAL 18–19% RATE, SUPPORTED BY STRONG API DEMAND, NEW PRODUCT LAUNCHES, REGULATORY APPROVALS & INTERNATIONAL EXPANSION • MANAGEMENT EXPECTS CORE API BUSINESS TO SUSTAIN APPROXIMATELY 18–19% MEDIUM-TERM GROWTH, DRIVEN BY IMMUNOSUPPRESSANTS, ANTI-INFECTIVES, ANTIFUNGALS & ONCOLOGY PRODUCTS • MANAGEMENT TARGETS EBITDA MARGIN RECOVERY TOWARD 38–40% OVER THE NEXT FEW YEARS, SUPPORTED BY HIGHER CAPACITY UTILIZATION, STELLON SCALE-UP & NORMALIZATION OF RAW MATERIAL COSTS • MANAGEMENT EXPECTS SOME INJECTABLE MANUFACTURING CONTRACTS TO MATERIALIZE IN H2 FY27, WITH MULTIPLE DOMESTIC & INTERNATIONAL CUSTOMERS IN ADVANCED DISCUSSIONS • MANAGEMENT TARGETS APPROXIMATELY ₹300 CR INJECTABLE BUSINESS REVENUE OVER THE NEXT 3–4 YEARS, SUPPORTED BY CONTRACT MANUFACTURING OPPORTUNITIES & UTILIZATION RAMP-UP • MANAGEMENT EXPECTS MEANINGFUL US FORMULATION REVENUE CONTRIBUTION THROUGH STELLON BIOTECH TO BEGIN BUILDING IN H2 FY27, FOLLOWING PRODUCT APPROVALS & INITIAL COMMERCIAL SUPPLIES • MANAGEMENT SEES POTENTIAL TO SCALE ITS NEW INSPIRA DERMATOLOGY BUSINESS TO ₹400–500 CR OVER APPROXIMATELY 4–5 YEARS, TARGETING AN ADDRESSABLE INDIAN MARKET OF AROUND ₹5,000 CR • MANAGEMENT PLANS CAPITAL EXPENDITURE OF APPROXIMATELY ₹50–60 CR ANNUALLY IN FY27 & FY28, WHILE MAINTAINING AN EXPECTED EFFECTIVE TAX RATE OF 24–25% • Q2 REVENUE SURGED 25% YOY TO ₹309.1 CR FROM ₹247.1 CR, SUPPORTED BY BROAD-BASED API DEMAND, NEW CUSTOMERS & STRONGER INTERNATIONAL BUSINESS • Q2 EBITDA GREW 18% YOY TO ₹104.4 CR, WHILE EBITDA MARGIN DECLINED TO 33.8% FROM APPROXIMATELY 35.8% DUE TO RAW MATERIAL INFLATION & NEW BUSINESS EXPENSES • Q2 PAT INCREASED 10.3% YOY TO ₹69.6 CR, WITH PAT MARGIN AT APPROXIMATELY 22.5% • H1 FY27 REVENUE GREW 26% YOY TO ₹566.6 CR, WHILE EBITDA INCREASED 25% TO ₹187 CR & PAT GREW 19% TO ₹127.3 CR • H1 EBITDA MARGIN REMAINED BROADLY STABLE AT 33% VS 33.2% LAST YEAR, DESPITE HIGHER SOLVENT COSTS, ENERGY EXPENSES & PRODUCT MIX PRESSURES • API BUSINESS REVENUE SURGED 30% YOY TO ₹250.1 CR IN Q2, CONTRIBUTING APPROXIMATELY 81% OF TOTAL REVENUE • DOMESTIC API BUSINESS GREW 42% YOY, WHILE API EXPORTS INCREASED 8%, WITH THE US, LATIN AMERICA & JAPAN REMAINING IMPORTANT GROWTH MARKETS • FORMULATION BUSINESS REVENUE GREW 6% YOY TO ₹58.9 CR, WHILE DOMESTIC FORMULATION SALES INCREASED 29%, OFFSET BY CUSTOMER TRANSITIONS FROM FORMULATIONS TO APIs IN SOME EXPORT MARKETS • COMPANY HAS OVER 30 API PRODUCTS IN ITS PORTFOLIO, WITH AN ADDITIONAL 10–15 PRODUCTS UNDER DEVELOPMENT ACROSS SPECIALIZED THERAPEUTIC CATEGORIES • NYSTATIN IS GAINING TRACTION WITH MULTIPLE US CUSTOMER QUALIFICATIONS, WHILE FUSIDIC ACID COMMERCIALIZATION, FIDAXOMICIN REGULATORY FILINGS & ROMIDEPSIN CUSTOMER LAUNCHES SUPPORT FUTURE GROWTH • MANUFACTURING UTILIZATION STOOD AT 75% FOR UNIT I APIs, 21% FOR UNIT II FORMULATIONS, 55% FOR UNIT III APIs & ONLY 5% FOR UNIT IV INJECTABLES • UNIT IV INJECTABLE FACILITY OFFERS SIGNIFICANT OPERATING LEVERAGE POTENTIAL, WITH HIGHER UTILIZATION EXPECTED TO IMPROVE FIXED-COST ABSORPTION & CONSOLIDATED EBITDA MARGINS • MANAGEMENT INDICATED MULTIPLE LARGE CUSTOMERS HAVE COMPLETED INJECTABLE FACILITY AUDITS, WITH CONTRACT NEGOTIATIONS PROGRESSING TOWARD POTENTIAL COMMERCIAL ORDERS • US SUBSIDIARY STELLON BIOTECH RECEIVED APPROVALS FOR TOFACITINIB & MYCOPHENOLATE MOFETIL ORAL SUSPENSION, WITH INITIAL TOFACITINIB SUPPLIES ALREADY COMMENCED • MANAGEMENT EXPECTS MYCOPHENOLATE MOFETIL ORAL SUSPENSION SUPPLIES TO FOLLOW, SUPPORTING US MARKET PENETRATION & FUTURE FORMULATION REVENUE • Q2 GROSS MARGIN DECLINED APPROXIMATELY 400 BPS YOY TO 76.2%, REFLECTING HIGHER RAW MATERIAL COSTS, ENERGY EXPENSES & AN UNFAVORABLE API PRODUCT MIX • Q2 EBITDA MARGIN EXCLUDING STELLON & NEW INJECTABLE BUSINESS COSTS STOOD AT APPROXIMATELY 37.1%, COMPARED WITH REPORTED CONSOLIDATED MARGIN OF 33.8% • MANAGEMENT PLANS TO IMPROVE PROFITABILITY THROUGH PRODUCTIVITY GAINS, R&D-LED COST REDUCTIONS, INVENTORY MANAGEMENT & RENEWABLE ENERGY INVESTMENTS • CDMO BUSINESS CURRENTLY HAS ONE COMMERCIAL PROJECT & MULTIPLE DEVELOPMENT-STAGE ENGAGEMENTS, WITH AN APPROXIMATELY $2 MILLION ANNUAL COMMERCIAL OPPORTUNITY DISCUSSED DURING THE CALL • COMPANY LAUNCHED INSPIRA, A DEDICATED DERMATOLOGY DIVISION TARGETING ECZEMA, FUNGAL INFECTIONS, BACTERIAL SKIN CONDITIONS & ACNE THROUGH ITS SPECIALIZED PRODUCT PORTFOLIO • UNIT II FORMULATION FACILITY SUCCESSFULLY COMPLETED A USFDA INSPECTION, WHILE UNIT III LIMBASI RECEIVED ANVISA APPROVAL, SUPPORTING ACCESS TO REGULATED MARKETS • COMPANY MAINTAINED A ZERO-DEBT BALANCE SHEET WITH APPROXIMATELY ₹445 CR CASH & CASH EQUIVALENTS AS OF SEPTEMBER 2026, PROVIDING FINANCIAL FLEXIBILITY FOR FUTURE EXPANSION • MANAGEMENT REMAINS POSITIVE ON API GROWTH, INJECTABLE CONTRACTS, US FORMULATION EXPANSION, CDMO OPPORTUNITIES & DERMATOLOGY SCALE-UP, BUT RAW MATERIAL INFLATION, LOW INJECTABLE UTILIZATION, STELLON EXPENSES & DELAYED COMMERCIALIZATION REMAIN KEY RISKS KEY MONITORABLE: FY27 REVENUE GROWTH ABOVE 18–19%, PROGRESS TOWARD 38–40% EBITDA MARGINS, H2 INJECTABLE CONTRACT WINS, STELLON US REVENUE CONTRIBUTION & IMPROVEMENT IN UNIT IV CAPACITY UTILIZATION. Note: The ₹300 Cr injectable and ₹400–500 Cr dermatology targets are long-term management ambitions, not confirmed FY27 revenue guidance.
CONCORD BIOTECH LIMITED